## **Core Concept**
Obsessive Compulsive Disorder (OCD) is an anxiety disorder characterized by recurrent, intrusive thoughts (obsessions) and repetitive behaviors (compulsions). The first-line treatment for OCD often involves medications that target serotonin and/or dopamine systems. Selective serotonin reuptake inhibitors (SSRIs) are commonly used due to their efficacy and relatively favorable side effect profile.
## **Why the Correct Answer is Right**
The correct answer, , is a drug of choice for OCD because it is an SSRI. SSRIs work by inhibiting the reuptake of serotonin in the brain, which increases the availability of serotonin in the synaptic cleft and can help reduce symptoms of OCD. has been shown in numerous clinical trials to be effective in reducing the symptoms of OCD, such as obsessions and compulsions, with a relatively good safety and tolerability profile.
## **Why Each Wrong Option is Incorrect**
- **Option A:** is not typically used as a first-line treatment for OCD. It might have some off-label uses but is not preferred due to its side effect profile and the availability of better-tolerated options.
- **Option B:** is a tricyclic antidepressant (TCA) that does have some efficacy in treating OCD but is not considered a first-line treatment due to its side effects and the availability of safer alternatives like SSRIs.
- **Option D:** might be used in certain cases of treatment-resistant OCD or for specific symptoms, but it is not a first-line treatment for OCD in adults.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that SSRIs are considered first-line pharmacotherapy for OCD due to their efficacy and safety profile. Among SSRIs, is notable for its effectiveness and is often listed as a preferred agent. It's also important to note that while SSRIs are effective, they may take several weeks to start showing benefits.
## **Correct Answer:** . Fluoxetine
Free Medical MCQs Β· NEET PG Β· USMLE Β· AIIMS
Access thousands of free MCQs, ebooks and daily exams.
By signing in you agree to our Privacy Policy.